Zainal Baharin Nurul Hana, Khairil Mokhtar Nur Fadhilah, Mohd Desa Mohd Nasir, Gopalsamy Banulata, Mohd Zaki Nor Nadiha, Yuswan Mohd Hafis, Muthanna AbdulRahman, Dzaraly Nurul Diana, Abbasiliasi Sahar, Mohd Hashim Amalia, Abdullah Sani Muhamad Shirwan, Mustafa Shuhaimi
Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Laboratory of Halal Science Research, Halal Products Research Institute, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
PeerJ. 2021 Dec 14;9:e12193. doi: 10.7717/peerj.12193. eCollection 2021.
The emergence of antibiotic-resistant bacteria has become a significant and ever-increasing threat to global public health, increasing both morbidity and mortality rates, and the financial burden on health services. Infection by drug-resistant bacteria is anticipated to contribute to the demise of almost 10 million people by the year 2050 unless a competent and effective response is devised to engage with this issue. The emergence and spread of resistance are commonly caused by the excessive or inappropriate use of antibiotics and substandard pharmaceuticals. It arises when pathogens adapt to different conditions and develop self-defence mechanisms. Currently, novel antimicrobial peptides (AMPs) have been reported to be the sole cure for some clinical cases of infectious diseases such as sepsis and skin infections, although these agents may, on occasion, require administration together with an adjunctive low-dose antibiotic. Although AMPs are a promising alternative form of anti-microbial therapy and easily applied in the medical sector, they still have limitations that should not be taken lightly. Hence, this review explores the characteristics, advantages and disadvantages of AMPs for their potential in treating antibiotic-resistant pathogens.
抗生素耐药细菌的出现已成为对全球公共卫生的重大且日益严重的威胁,导致发病率和死亡率上升,以及卫生服务的经济负担加重。预计到2050年,耐药细菌感染将导致近1000万人死亡,除非制定出有效应对这一问题的措施。耐药性的出现和传播通常是由抗生素和不合格药品的过度使用或不当使用引起的。当病原体适应不同条件并形成自我防御机制时,就会产生耐药性。目前,有报道称新型抗菌肽(AMPs)是治疗某些传染病临床病例(如败血症和皮肤感染)的唯一疗法,尽管这些药物有时可能需要与低剂量辅助抗生素联合使用。尽管抗菌肽是一种有前景的抗菌治疗替代形式,且易于应用于医疗领域,但它们仍然存在不容忽视的局限性。因此,本综述探讨了抗菌肽在治疗耐药病原体方面的特性、优点和缺点。